Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.

OBJECTIVE The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. In Japan, product labels were revised in April 2007 to recommend periodic echocardiography for patients taking these dopamine agonists, however, the compliance of physicians to follow through with this recommendation is unknown. This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. METHODS AND PATIENTS Medical claim data from January 2005 to December 2008 were used. Patients were divided into a C-P group (prescribed either cabergoline or pergolide) or reference group (prescribed other anti-PD drugs), and further classified based on whether they were prescribed these drugs "pre-revision" or "post-revision." The Cochran-Armitage trend test was used to compare the proportion of echocardiograms obtained amongst these groups before and after the revision. The frequencies of echocardiograms performed among the treatment groups for each period were compared by Fisher's exact test. RESULTS A total of 222 subjects (C-P, 73; reference, 149) were assessed. The proportion of C-P patients undergoing echocardiography increased from 4.8% to 27.9% after revision of product labels (p=0.001), which was higher than those in the reference group following label revisions (11.0%) (p=0.014). Prescription duration of C-P after the revision was longer in the patients with echocardiography than without echocardiography (p=0.026). CONCLUSION Although echocardiography evaluations increased, more than 70% of PD patients prescribed cabergoline or pergolide did not undergo such assessment despite the product label recommendation. Adherence to drug safety recommendations should be facilitated with more feasible and effective measures.

[1]  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review , 2009, Journal of Neural Transmission.

[2]  Jeroen J. Bax,et al.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  T. Nakayama,et al.  Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. , 2006, Neurology.

[4]  N. Hattori,et al.  The frequency of cardiac valvular regurgitation in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  John G Nutt,et al.  Clinical practice. Diagnosis and initial management of Parkinson's disease. , 2005, The New England journal of medicine.

[6]  M. Heckman,et al.  Valvular heart disease in patients taking pergolide. , 2005, Mayo Clinic proceedings.

[7]  H. Horiguchi,et al.  Difference in resource utilization between patients with acute and chronic heart failure from Japanese administrative database. , 2010, International journal of cardiology.

[8]  M. Kulldorff,et al.  Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.

[9]  D. Graham,et al.  A study of compliance with FDA recommendations for pemoline (Cylert). , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  W. Edwards,et al.  Valvular heart disease in patients taking pergolide. , 2002, Mayo Clinic proceedings.

[11]  A. Verma,et al.  Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation , 2008 .

[12]  Michael J. Goodman,et al.  Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.

[13]  Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists , 2007, European journal of neurology.

[14]  J. Marc Overhage,et al.  Research Paper: A Randomized Trial of "Corollary Orders" to Prevent Errors of Omission , 1997, J. Am. Medical Informatics Assoc..

[15]  V. D. Hsu,et al.  Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program , 2005, Pharmacoepidemiology and drug safety.

[16]  C. Szmigielski,et al.  Valvular heart disease and the use of cabergoline for the treatment of prolactinoma , 2009, Clinical endocrinology.

[17]  A. Verma.  Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease , 2008 .

[18]  M. Maggini,et al.  Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. , 2001, JAMA.

[19]  Ut Southwestern.  Pergolide use in Parkinson disease is associated with cardiac valve regurgitation , 2005 .

[20]  Y. Narita,et al.  [Analysis of application form for Parkinson's disease provided by the specific diseases treatment research program of Ministry of Health, Labour and Welfare of Japan]. , 2008, Rinsho shinkeigaku = Clinical neurology.

[21]  J. Campbell,et al.  Medical care in Japan. , 1995, The New England journal of medicine.

[22]  S. Ikeda,et al.  Development of a Database of Health Insurance Claims: Standardization of Disease Classifications and Anonymous Record Linkage , 2010, Journal of epidemiology.

[23]  John G. Nutt,et al.  Diagnosis and Initial Management of Parkinson's Disease , 2005 .

[24]  Kaveh G Shojania,et al.  Effect of point-of-care computer reminders on physician behaviour: a systematic review , 2010, Canadian Medical Association Journal.

[25]  T. Chuma,et al.  [A guideline for the treatment of Parkinson's disease]. , 2002, Rinsho shinkeigaku = Clinical neurology.

[26]  Kenji Nakashima,et al.  Changes in Prevalence and Incidence of Parkinson’s Disease in Japan during a Quarter of a Century , 2009, Neuroepidemiology.

[27]  D Fife,et al.  Coprescribing and codispensing of cisapride and contraindicated drugs. , 2001, JAMA.

[28]  W Poewe,et al.  Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease , 2006, European journal of neurology.

[29]  Y. Doi,et al.  Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district , 2011, Acta neurologica Scandinavica.

[30]  Patrick Santens,et al.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.

[31]  H. Fukuda,et al.  Change in clinical practice after publication of guidelines on breast cancer treatment. , 2009, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  Elena S. Di Martino,et al.  Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies , 2008, Journal of endocrinological investigation.